sacituzumab govitecan
gilead sciences
['tnbc', 'breast', 'gilead']
we presented final analysis results from a phase 3 study in 2l metastatic triple-negative breast cancer (#tnbc) at #asco22. read more. 
The impossible is not impossible. It’s simply what hasn’t been achieved yet. Twitter guidelines: https://t.co/vWkdtfUf7N